Literature DB >> 21088155

Viral drug sensitivity testing using quantitative PCR: effect of tyrosine kinase inhibitors on polyomavirus BK replication.

Parmjeet S Randhawa1, Noush A Farasati, Yuchen Huang, Markus Y Mapara, Ron Shapiro.   

Abstract

Our objective was to determine whether quantitative polymerase chain reaction (PCR) can be used to measure the effect of tyrosine kinase (TK) inhibition on polyomavirus BK (BKV) replication. The BKV was grown in a cell culture system. The rate of viral replication in the presence or absence of the drug being tested was assessed by amplifying the viral genome using primers directed against the viral capsid 1 protein. Dasatinib, erlotinib, gefitinib, imatinib, sunitinib, and sorafenib all showed antiviral activity at micromolar concentrations. The 50% effective concentration for erlotinib and sorafenib was within blood concentrations readily achieved in human subjects. Quantitative PCR is a convenient method for viral drug sensitivity testing for slow-growing viruses that do not readily produce cytopathic effect. TK inhibitors deserve further consideration as a potential therapeutic option for BKV-associated nephropathy and hemorrhagic cystitis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21088155      PMCID: PMC3075568          DOI: 10.1309/AJCP7JYHJN1PGQVC

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  24 in total

1.  Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.

Authors:  Dirk Strumberg; Heike Richly; Ralf A Hilger; Norbert Schleucher; Sonke Korfee; Mitra Tewes; Markus Faghih; Erich Brendel; Dimitris Voliotis; Claus G Haase; Brian Schwartz; Ahmad Awada; Rudolf Voigtmann; Max E Scheulen; Siegfried Seeber
Journal:  J Clin Oncol       Date:  2004-12-21       Impact factor: 44.544

2.  Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies.

Authors:  M Hidalgo; L L Siu; J Nemunaitis; J Rizzo; L A Hammond; C Takimoto; S G Eckhardt; A Tolcher; C D Britten; L Denis; K Ferrante; D D Von Hoff; S Silberman; E K Rowinsky
Journal:  J Clin Oncol       Date:  2001-07-01       Impact factor: 44.544

3.  Effect of leflunomide and cidofovir on replication of BK virus in an in vitro culture system.

Authors:  Noush Afarin Farasati; Ron Shapiro; Abhay Vats; Parmjeet Randhawa
Journal:  Transplantation       Date:  2005-01-15       Impact factor: 4.939

4.  Antiviral activity of gyrase inhibitors norfloxacin, coumermycin A1 and nalidixic acid.

Authors:  E Ferrazzi; M Peracchi; M A Biasolo; O Faggionato; S Stefanelli; G Palù
Journal:  Biochem Pharmacol       Date:  1988-05-01       Impact factor: 5.858

5.  Activation of CREB/ATF sites by polyomavirus large T antigen.

Authors:  Tara M Love; Rowena de Jesus; Jennifer A Kean; Qing Sheng; Andrew Leger; Brian Schaffhausen
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

6.  Abl family tyrosine kinases regulate sialylated ganglioside receptors for polyomavirus.

Authors:  Alyson I Swimm; William Bornmann; Mengxi Jiang; Michael J Imperiale; Aron E Lukacher; Daniel Kalman
Journal:  J Virol       Date:  2010-02-24       Impact factor: 5.103

7.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.

Authors:  B J Druker; M Talpaz; D J Resta; B Peng; E Buchdunger; J M Ford; N B Lydon; H Kantarjian; R Capdeville; S Ohno-Jones; C L Sawyers
Journal:  N Engl J Med       Date:  2001-04-05       Impact factor: 91.245

8.  Infection of vero cells by BK virus is dependent on caveolae.

Authors:  Sylvia Eash; William Querbes; Walter J Atwood
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

9.  The in vitro effect of monensin on BK polyomavirus replication.

Authors:  V Pietropaolo; A M Degener; C Di Taranto; L Sinibaldi; N Orsi
Journal:  New Microbiol       Date:  1995-10       Impact factor: 2.479

Review 10.  Viruses and cancer: lessons from the human polyomavirus, JCV.

Authors:  Krzysztof Reiss; Kamel Khalili
Journal:  Oncogene       Date:  2003-09-29       Impact factor: 9.867

View more
  5 in total

Review 1.  Management of polyomavirus-associated nephropathy in renal transplant recipients.

Authors:  Dirk R J Kuypers
Journal:  Nat Rev Nephrol       Date:  2012-04-17       Impact factor: 28.314

2.  Mechanism Prediction of Astragalus membranaceus against Cisplatin-Induced Kidney Damage by Network Pharmacology and Molecular Docking.

Authors:  Congchao Jia; Xianchao Pan; Binyou Wang; Pengyu Wang; Yiwei Wang; Rong Chen
Journal:  Evid Based Complement Alternat Med       Date:  2021-08-19       Impact factor: 2.629

Review 3.  Middle East Respiratory Syndrome and Severe Acute Respiratory Syndrome: Current Therapeutic Options and Potential Targets for Novel Therapies.

Authors:  Julie Dyall; Robin Gross; Jason Kindrachuk; Reed F Johnson; Gene G Olinger; Lisa E Hensley; Matthew B Frieman; Peter B Jahrling
Journal:  Drugs       Date:  2017-12       Impact factor: 9.546

Review 4.  Tumor Restrictions to Oncolytic Virus.

Authors:  Markus Vähä-Koskela; Ari Hinkkanen
Journal:  Biomedicines       Date:  2014-04-17

5.  The clinically approved drugs amiodarone, dronedarone and verapamil inhibit filovirus cell entry.

Authors:  Gerrit Gehring; Katrin Rohrmann; Nkacheh Atenchong; Eva Mittler; Stephan Becker; Franziska Dahlmann; Stefan Pöhlmann; Florian W R Vondran; Sascha David; Michael P Manns; Sandra Ciesek; Thomas von Hahn
Journal:  J Antimicrob Chemother       Date:  2014-04-07       Impact factor: 5.790

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.